NEW YORK, Sept. 2, 2025 /PRNewswire/ — Integrated Sensing and Communications (ISAC) is a key concept being developed for 6G, which transforms cellular networks into radars and allows them to both sense their environment and communicate information about it. Although there are significant technical challenges to bring this to market, it is a concept that can revolutionize mobile networks and allow Mobile Network Operators (MNOs) to finally become much more than a data pipe, according to ABI Research, a global technology intelligence firm. The commercial opportunities for ISAC are substantial and offer MNOs a chance to get into new markets, parts of which are not served by other technologies or companies.

“ISAC is a unique opportunity for mobile operators to break free of their connectivity legacy,” said Dimitris Mavrakis, Senior Research Director at ABI Research. “Coupled with network APIs, they can become brokers for location and positioning across their network footprint, helping enterprises locate their assets and protect their locations. Mobile operators cannot afford to ignore ISAC, as it is key for them to continue growing their business. It is the first truly innovative concept discussed for cellular networks since 4G introduced mobile broadband.”

In 2025, vendors and mobile operators are conducting live commercial trials to understand the technical and commercial implications of deploying ISAC, while ETSI, 3GPP, and other industry bodies are continuing their standardization efforts. Initial trials in China indicate that there is some commercial interest in sensing, mostly driven by the low-altitude economy, but it is still too early to understand if the new technology makes commercial sense. The challenge is compounded by the fact that a fully capable ISAC radio is not backward compatible with existing 5G infrastructure, meaning that an upgrade could cost upwards of $50,000 to $100,000 per cell site. This may not be something mobile operators are willing to risk at the current stage of the market, but demand and economies of scale will bring prices down while exposing the market to ISAC’s capabilities.

ISAC is a unique and challenging opportunity, and vendors are currently investing in R&D and filing for relevant patents. Although it’s early, ISAC has the capability to completely redefine the market and upset the long-established dynamics while creating burgeoning new ecosystem. As such, early adopters are starting to assess the technology today, when the interest, hype, and investment around ISAC is just ramping up.

These findings are from ABI Research’s Integrated Sensing and Communications: Market Developments & Use Case Analysis report, part of the company’s 5G, 6G, and Open RAN research service, which includes research, data, and ABI Insights. 

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info: 

Global
Jason Scheer
Tel: +1.516.624.2558
pr@abiresearch.com 

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 – 15 in Copenhagen, Denmark:

• EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS^® PathFinder^™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients.
• NEW STANDARDS IN SURGICAL EXCELLENCE: showcasing the DORC EVA NEXUS^™ dual strategy surgical platform as part of ZEISS’s expanding surgical workflow solutions.
• IMPROVED PREDICTABILITY OUTCOMES: updated ZEISS VISULYZE 1.2 data analysis and personalized nomogram creation software tool now with ZEISS FORUM integration for more convenient and efficient nomogram creation within the ZEISS Corneal Refractive Workflow.
• REFRACTIVE INDUSTRY MILESTONES: more than 12 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; also celebrating ongoing market traction of SMILE^® pro for treating hyperopia.
• CATARACT MILESTONES: celebrating more than 10 million cataract surgeries using VisionBlue^® anterior stain from DORC, a ZEISS company; celebrating key IOL milestones validated by multiple clinical studies presented at ESCRS.

JENA, Germany, Sept. 2, 2025 /PRNewswire/ — ZEISS Medical Technology showcases the latest innovations and enhancements to its cataract and corneal refractive workflow solutions, from diagnostics and surgical planning to advanced treatments, at the European Society of Cataract and Refractive Surgeons (ESCRS) conference in Copenhagen, Denmark, from Sept. 12-15, 2025.

ZEISS VISULYZE 1.2 software

“ZEISS continues to introduce advanced optical and digital innovation to meet the expanding needs of Europe’s leading refractive and cataract surgeons,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “From major industry milestones to new digital workflow solutions, our industry leadership shines bright, setting new standards for ophthalmic care.”

Advancements deliver improved efficiencies in surgical planning

From advanced imaging to cloud-enabled data access, ZEISS diagnostic and digital solutions integrated into ophthalmic workflows can help surgeons visualize more, connect insights across a workflow, and make data-driven decisions, including earlier detection of eye conditions that may affect surgical planning and outcomes. At ESCRS, ZEISS will demonstrate a fully integrated solution connecting cataract and glaucoma workflows to support more efficient and confident decision making.

Glaucoma is the most common comorbidity in cataract surgery. According to a recent study¹, around 20% of patients who undergo cataract procedures also have glaucoma or ocular hypertension. ZEISS offers integrated diagnostic and therapeutic solutions to support earlier detection and management of glaucoma in cataract patients, helping to improve long-term outcomes of cataract surgery. Devices including the ZEISS SL 800, CLARUS^®, CIRRUS^® OCT, ARTEVO^® 750, and VISULAS^® combi (yag/slt) are shared across the cataract and glaucoma workflows and seamlessly connected via FORUM^® for complete data continuity.

“It’s an exciting time to be an ophthalmologist. I’m extremely grateful to companies like ZEISS Medical Technology, that bring us products which are truly game changers in the care of our glaucoma and cataract patients,” said Dr. Steven Vold, Founder and Chief Executive Officer of Vold Vision (Florida, USA).

ZEISS will also showcase CIRRUS^® PathFinder™, which recently received CE mark approval, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician’s patient care workflow with OCT interpretation assistance, supporting improved surgical planning, particularly for high-volume clinics. The AI-powered OCT assessment tool is fully integrated into ZEISS CIRRUS², using proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed capability of the latest CIRRUS software release, helping to improve a practice’s efficiency and patient care outcomes.

At ESCRS, the company will celebrate ZEISS CIRRUS PathFinder as a major step forward in AI and diagnostics, unveiling the progress made to date with the latest innovation in CIRRUS OCT technology including a presentation by Dr. Leo Seo Wei, MD, sharing her first impressions and expertise on Sunday, Sept. 14, at 3:00 PM CET in the ZEISS booth #C1.130.  

Leading the way in refractive surgery with SMILE^® pro for hyperopia and advanced digitally connected patient planning

The ZEISS Corneal Refractive Workflow empowers surgeons to optimize patient flow while growing their practice with added value beyond the devices through targeted services that help improve patient outcomes through a digitally connected and streamlined clinical workflow. At ESCRS, ZEISS will showcase a new version of its comprehensive data analysis and personalized nomogram creation software tool, ZEISS VISULYZE 1.2, now connected to ZEISS FORUM so refractive surgeons can access their imported data with one click, offering convenience and efficiency during the nomogram creation process. The software update provides transparency into factors that can affect patient outcomes, allowing those insights to be transferred to the refractive laser as well as to the next treatment plan, reducing manual work and risks of transcription errors. With ZEISS FORUM integration, the ZEISS VISULYZE 1.2 software helps improve predictability and outcomes to support higher patient satisfaction.

ZEISS continues to extend its global refractive industry momentum with the celebration of more than 12 million eyes treated with ZEISS SMILE and ZEISS SMILE pro, reflecting the growing international adoption of the technology for a minimal invasive lenticule extraction procedure. The company is also celebrating one year of SMILE^® pro for treating hyperopia, now available in 56 countries. ZEISS is the only provider offering a treatment for hyperopia with lenticule extraction, representing a promising advancement in refractive surgery with outcomes comparable to hyperopic LASIK. ZEISS SMILE and ZEISS SMILE pro continue to be leading solutions trusted by surgeons for the technology’s proven reliability and effective treatment with the VisuMax^® and VISUMAX^® 800 from ZEISS.

ESCRS attendees can learn more about the latest refractive offerings within the ZEISS Corneal Refractive Workflow at the ZEISS booth #C1.130, including a presentation on Sunday, Sept. 14, at 10:00 AM CET from Prof. Dr. Dan Reinstein, London Vision Clinic (UK), who will share his expert insights and valuable firsthand experience with ZEISS SMILE pro for hyperopia.

Celebrating industry milestones and unparalleled optics within an integrated cataract workflow

Setting new standards in surgical excellence, ZEISS is delivering industry-leading efficiency through digitally integrated solutions and unparalleled optics. At ESCRS, the ZEISS Cataract Workflow will include a robust portfolio of surgical solutions, including the 3D heads-up technology of the ZEISS ARTEVO 850, optical visualization with a novel light source with the ZEISS ARTEVO 750, the ZEISS EQ Workplace and ZEISS Surgery Planner digital cataract planning solutions, and the patented ZEISS QUATTRO pump of the QUATERA^® 700 from ZEISS to experience chamber stability independent of IOP and flow. ZEISS will also showcase next to its primary cataract workflow the DORC EVA NEXUS™ platform, uniquely suited to address both retina and cataract surgery, now with availability of angled EquiPhaco designed for optimal irrigation flow. EquiPhaco, combined with EVA NEXUS SMART IOP™, allows for a more stable, lower anterior chamber pressure during procedures.

ZEISS is also celebrating key product milestones, including a special event with Dr. Elena Barraquer in the ZEISS booth #C1.130 on Saturday, Sept. 13, at 3:00 PM CET to highlight more than 10 million cataract surgeries conducted using VisionBlue^® anterior stain from DORC, reflecting the solution’s continued leadership in the market as the only trypan blue stain for anterior use approved by the FDA and now approved for staining of Descemet’s membrane and trabecular meshwork.

Additionally, ZEISS is celebrating IOL clinical milestones which reflect the company’s expertise in optics, featuring two distinct high-quality biomaterials and lens designs. Dr. Andrea Janeková from Eye Center Prague in Czech Republic says, “As the first peer-reviewed study on the AT ELANA^® 841P, the data confirm that it delivers excellent distance, intermediate, and near vision with minimal photic phenomena, meeting the expectations of both surgeons and patients. What stood out most to me was the smooth and extended defocus profile of the AT ELANA 841P, which translated into functional vision across a wide range and high patient satisfaction.” Dr. Mfazo Hove from Blue Fin Vision in the UK says, “I knew the AT LISA^® tri lenses were good – my patients repeatedly told me. They have exceeded all my expectations since having them implanted 18 months ago. I might even have become a better surgeon – the numbers don’t lie. PC rupture 0.2% off 5,600 operations in 12 months down from 0.27%.”

As part of an IOL clinical milestone celebration in the ZEISS booth #C1.130 on Saturday, Sept. 13, at 10:00 AM CET, the ZEISS IOL portfolio will be validated through multiple clinical studies and direct ZEISS IOL experience presented by industry experts including Prof. Gerd U. Auffarth (Heidelberg, Germany) and Dr. Kyungmin Koh (Seoul, Republic of Korea), as well as Dr. Andrea Janeková and Dr. Mfazo Hove.

ZEISS will showcase its latest offerings and new innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference from Sept. 12 – 15, 2025, at booth #C1.130.

For more information, visit www.zeiss.com/med.  

¹ Skalicky, S.E., Martin, K.R., Fenwick, E., Crowston, J.G., Goldberg, I. and McCluskey, P. (2015), Cataract and quality of life in glaucoma. Clin Experiment Ophthalmol, 43: 335-341. https://doi.org/10.1111/ceo.12454.
² ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

Contact for investors
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.med@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

www.zeiss.com/newsroom

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med 

CIRRUS® PathFinder™ AI-powered OCT assessment tool

DORC EVA NEXUS™

Celebrating more than 12 million eyes treated with SMILE® and SMILE® pro from ZEISS.

Celebrating more than 10 million cataract surgeries conducted using VisionBlue® anterior stain from DORC.

BMNR investor presentation walks you through “the Alchemy of 5%”

BitMine Crypto + Cash Holdings of $8.98 billion, including 1.87 million ETH Tokens

BitMine remains supported by a premier group of institutional investors including ARK’s Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, and Galaxy Digital to support BitMine’s goal of acquiring 5% of ETH

LAS VEGAS, Sept. 2, 2025 /PRNewswire/ — (NYSE AMERICAN: BMNR) BitMine Immersion Technologies (“BitMine” or the “Company”) today announced the release of the latest investor presentation deck on its website titled “the Alchemy of 5%” and August monthly video series called “The Chairman’s Message.”

Hosted by Thomas “Tom” Lee, Chairman of BitMine and co-founder of Fundstrat, the Chairman’s Message video series was developed to help inform investors on the long-term upside of Ethereum and to provide insights into the company’s ETH treasury strategy. The investor presentation, titled “the Alchemy of 5%,” accompanies the video.

“In this latest message, we discuss how 2025 and the SEC Project Crypto and GENIUS Act are creating a multi-decade opportunity for ethereum and ETH, similar to the transformation seen on Wall Street after the USD formally went off the gold standard in 1971. While many investors bought Gold in 1971, the real opportunity was seen by the massive innovation unleashed by Wall Street in the decades after 1971. This same supercycle is happening today for ethereum” said Tom Lee, Chairman of BitMine. 

Both the “Chairman’s Message” and investor presentation are available on the website: https://bitminetech.io/investor-relations/

Also, BitMine today announced crypto + cash holdings of $8.98 billion. As of August 31st at 5:00pm ET, the Company’s crypto holdings are comprised of 1,866,974 ETH at $4,458 per ETH (Bloomberg), 192 Bitcoin (BTC) and unencumbered cash of $635 million.

BitMine crypto holdings reigns as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc. (MSTR), which owns 629,376 BTC valued at $71 billion. 

BitMine remains the largest ETH treasury in the world. BitMine launched its ETH Treasury strategy on June 30th (closing on July 8th). In the ensuing seven weeks, the Company has passed many key milestones. 

The GENIUS Act and SEC’s Project Crypto are as transformational to financial services in 2025 as US action on August 15, 1971 ending Bretton Woods and the USD on the gold standard 54 years ago. This 1971 event was the catalyst for the modernization of Wall Street, creating the iconic Wall Street titans and financial and payment rails of today. These proved to be better investments than gold.

“We continue to believe Ethereum is one of the biggest macro trades over the next 10-15 years,” continued Lee. “Wall Street and AI moving onto the blockchain should lead to a greater transformation of today’s financial system. And the majority of this is taking place on Ethereum.”

BitMine is now one of the most widely traded stocks in the US. According to data from Fundstrat, the stock has traded average daily dollar volume of $2.3 billion (5-day average, as of August 24, 2025), ranking #22 in the US, behind Costco (rank #21) and ahead of JPMorgan (rank #27) and Marvel Technologies (rank #23) among 5,704 US-listed stocks (statista.com and Fundstrat research).

The company recently released a corporate presentation, which can be found here: https://bitminetech.io/investor-relations/

To stay informed, please sign up at: https://bitminetech.io/contact-us/

About BitMine
BitMine is a Bitcoin and Ethereum Network Company with a focus on the accumulation of Crypto for long term investment, whether acquired by our Bitcoin mining operations or from the proceeds of capital raising transactions. Company business lines include Bitcoin Mining, synthetic Bitcoin mining through involvement in Bitcoin mining, hashrate as a financial product, offering advisory and mining services to companies interested in earning Bitcoin denominated revenues, and general Bitcoin advisory to public companies. BitMine’s operations are located in low-cost energy regions in Trinidad; Pecos, Texas; and Silverton, Texas.

For additional details, follow on X:
https://x.com/bitmnr
https://x.com/fundstrat
https://x.com/bmnrintern

Forward Looking Statements
This press release contains statements that constitute “forward-looking statements.” The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. This document specifically contains forward-looking statements regarding progress and achievement of the Company’s goals regarding ETH acquisition and staking, the long-term value of Ethereum, continued growth and advancement of the Company’s Ethereum treasury strategy and the applicable benefits to the Company. In evaluating these forward-looking statements, you should consider various factors, including BitMine’s ability to keep pace with new technology and changing market needs; BitMine’s ability to finance its current business, Ethereum treasury operations and proposed future business; the competitive environment of BitMine’s business; and the future value of Bitcoin and Ethereum. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond BitMine’s control, including those set forth in the Risk Factors section of BitMine’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2025, as well as all other SEC filings, as amended or updated from time to time. Copies of BitMine’s filings with the SEC are available on the SEC’s website at www.sec.gov. BitMine undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

HONG KONG, Sept. 2, 2025 /PRNewswire/ — Cango Inc. (NYSE: CANG) (“Cango” or the “Company”) today published its Bitcoin production and mining operations update for August 2025.

Bitcoin Mining Production and Mining Operations Update for August 2025

Paul Yu, CEO and Director of Cango, commented, “With our new 50 EH/s deployed capacity now fully operational since July, our average operating hashrate has increased by 6.9% month-over-month. We are also pleased to share that we mined 663.7 Bitcoins this month, propelling our Bitcoin treasury past the 5,000 milestone. This achievement powerfully validates our strategy and strengthens our foundation for sustainable growth. Meanwhile, we have continued ramping up our core mining operations through targeted initiatives to boost fleet efficiency. This includes diligent maintenance of our existing fleet to ensure consistent operations, selective upgrading of older miners to next-generation models, and our recent acquisition of a 50 MW Bitcoin mining facility in the US state of Georgia. Looking ahead, we see significant potential to further optimize our operating efficiency and capture emerging opportunities in the energy and HPC sectors.”

About Cango Inc.

Cango Inc. (NYSE: CANG) is primarily engaged in the Bitcoin mining business, with operations strategically deployed across North America, the Middle East, South America, and East Africa. The Company entered the crypto asset space in November 2024, driven by advancements in blockchain technology, the growing adoption of digital assets, and its commitment to diversifying its business portfolio. In parallel, Cango continues to operate an online international used car export business through AutoCango.com, making it easier for global customers to access high-quality vehicle inventory from China. For more information, please visit: www.cangoonline.com.

Investor Relations Contact

Juliet YE, Head of Communications
Cango Inc.
Email: ir@cangoonline.com

Christensen Advisory
Tel: +852 2117 0861
Email: cango@christensencomms.com

DUBAI, UAE, Sept. 2, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is pleased to reveal the Sri Lankan chapter of the Bybit Rising Fund initiative in collaboration with Ceylon Cash, the driving force behind Web3Ceylon, Sri Lanka’s largest community-led blockchain education and adoption program. The joint initiative serves to promote Web3 literacy and empower the next generation of talent with a passion for blockchain technology and the digital economy.

Through Web3Ceylon, Bybit and Ceylon Cash will curate a series of educational seminars in Colombo (September 20, 2025), Galle (September 17, 2025), Kandy (September 28, 2025), and Ella (October 12, 2025) in Sri Lanka to build awareness and understanding of blockchain technologies. Newcomers, researchers, creators and builders stand to benefit from an effective and engaging introduction into the world of cryptocurrencies, distributed ledger technology, and on-chain security.

The four seminars aim to connect local builders, learners, and educators with experts at the forefront of blockchain innovation and safety, expanding access to the know-how and vision of a blockchain-enabled future for all, one city at a time.

Highlights

• Up to 600 seats available across four cities in Sri Lanka
• Knowledge transfer: Hands-on workshops and sessions on the basics of wallets, smart contracts, and building a Web3 project
• In-depth insights: Industry insiders and innovators will share real-world case studies of blockchain, diving into the technology, application and utility, and business layers of the technology
• Connecting with changemakers: Bringing together creators, builders, and entrepreneurs to shape the growth opportunities in Sri Lanka and meet the needs of local communities

Registration is required and subject to approval.

“At Bybit, we believe education is the first step toward building a sustainable Web3 future. Sri Lanka’s vibrant youth and entrepreneurial spirit make it an ideal place to nurture the next generation of blockchain innovators. Through this partnership with Ceylon Cash and Web3Ceylon, we aim to equip young people with the skills, knowledge, and opportunities they need to participate confidently in the digital economy and become active contributors to the global Web3 ecosystem,” said Nazar Tymoshchuk, Regional Manager at Bybit.

“We devise the seminars with everyone in mind: the speakers will cover everything from the basics to the technical aspects. Whether you are a developer eager to kick start your blockchain journey, a small business owner curious about crypto payments, or a student preparing yourself for the future of Web3, we have something to offer,” said Nisal Chandrasekara, Community Lead at Ceylon Cash.

With a fast-growing digital economy, high mobile penetration, and rising interest in blockchain and cryptocurrencies, Sri Lanka is well positioned to capture the transformative opportunities in Web3. As part of Bybit’s World Series of Trading (WSOT) 2025, the Bybit Rising Fund supports community-led initiatives that benefit local Web3 enthusiasts, builders, and educators.  

The Bybit Rising Fund is part of a community outreach program under WSOT 2025, to improve the access to and the quality of blockchain education in local communities. Registration is required for all events and subject to approval.

#Bybit / #TheCryptoArk  

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube